Skip to main content
Top
Published in: Journal of Hematology & Oncology 1/2013

Open Access 01-12-2013 | Research

Notch1 is required for hypoxia-induced proliferation, invasion and chemoresistance of T-cell acute lymphoblastic leukemia cells

Authors: Jie Zou, Peng Li, Fei Lu, Na Liu, Jianjian Dai, Jingjing Ye, Xun Qu, Xiulian Sun, Daoxin Ma, Jino Park, Chunyan Ji

Published in: Journal of Hematology & Oncology | Issue 1/2013

Login to get access

Abstract

Background

Notch1 is a potent regulator known to play an oncogenic role in many malignancies including T-cell acute lymphoblastic leukemia (T-ALL). Tumor hypoxia and increased hypoxia-inducible factor-1α (HIF-1α) activity can act as major stimuli for tumor aggressiveness and progression. Although hypoxia-mediated activation of the Notch1 pathway plays an important role in tumor cell survival and invasiveness, the interaction between HIF-1α and Notch1 has not yet been identified in T-ALL. This study was designed to investigate whether hypoxia activates Notch1 signalling through HIF-1α stabilization and to determine the contribution of hypoxia and HIF-1α to proliferation, invasion and chemoresistance in T-ALL.

Methods

T-ALL cell lines (Jurkat, Sup-T1) transfected with HIF-1α or Notch1 small interference RNA (siRNA) were incubated in normoxic or hypoxic conditions. Their potential for proliferation and invasion was measured by WST-8 and transwell assays. Flow cytometry was used to detect apoptosis and assess cell cycle regulation. Expression and regulation of components of the HIF-1α and Notch1 pathways and of genes related to proliferation, invasion and apoptosis were assessed by quantitative real-time PCR or Western blot.

Results

Hypoxia potentiated Notch1 signalling via stabilization and activation of the transcription factor HIF-1α. Hypoxia/HIF-1α-activated Notch1 signalling altered expression of cell cycle regulatory proteins and accelerated cell proliferation. Hypoxia-induced Notch1 activation increased the expression of matrix metalloproteinase-2 (MMP2) and MMP9, which increased invasiveness. Of greater clinical significance, knockdown of Notch1 prevented the protective effect of hypoxia/HIF-1α against dexamethasone-induced apoptosis. This sensitization correlated with losing the effect of hypoxia/HIF-1α on Bcl-2 and Bcl-xL expression.

Conclusions

Notch1 signalling is required for hypoxia/HIF-1α-induced proliferation, invasion and chemoresistance in T-ALL. Pharmacological inhibitors of HIF-1α or Notch1 signalling may be attractive interventions for T-ALL treatment.
Appendix
Available only for authorised users
Literature
1.
go back to reference Pui CH, Relling MV, Downing JR: Acute lymphoblastic leukemia. N Engl J Med. 2004, 350: 1535-1548. 10.1056/NEJMra023001.CrossRefPubMed Pui CH, Relling MV, Downing JR: Acute lymphoblastic leukemia. N Engl J Med. 2004, 350: 1535-1548. 10.1056/NEJMra023001.CrossRefPubMed
2.
go back to reference Weng AP, Ferrando AA, Lee W, Morris JP, Silverman LB, Sanchez-Irizarry C, Blacklow SC, Look AT, Aster JC: Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004, 306: 269-271. 10.1126/science.1102160.CrossRefPubMed Weng AP, Ferrando AA, Lee W, Morris JP, Silverman LB, Sanchez-Irizarry C, Blacklow SC, Look AT, Aster JC: Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004, 306: 269-271. 10.1126/science.1102160.CrossRefPubMed
4.
go back to reference Roy M, Pear WS, Aster JC: The multifaceted role of Notch in cancer. Curr Opin Genet Dev. 2007, 17: 52-59. 10.1016/j.gde.2006.12.001.CrossRefPubMed Roy M, Pear WS, Aster JC: The multifaceted role of Notch in cancer. Curr Opin Genet Dev. 2007, 17: 52-59. 10.1016/j.gde.2006.12.001.CrossRefPubMed
5.
go back to reference Sahlgren C, Gustafsson MV, Jin S, Poellinger L, Lendahl U: Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proc Natl Acad Sci U S A. 2008, 105: 6392-6397. 10.1073/pnas.0802047105.PubMedCentralCrossRefPubMed Sahlgren C, Gustafsson MV, Jin S, Poellinger L, Lendahl U: Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proc Natl Acad Sci U S A. 2008, 105: 6392-6397. 10.1073/pnas.0802047105.PubMedCentralCrossRefPubMed
6.
go back to reference Bray SJ: Notch signalling: a simple pathway becomes complex. Nat Rev Mol Cell Biol. 2006, 7: 678-689. 10.1038/nrm2009.CrossRefPubMed Bray SJ: Notch signalling: a simple pathway becomes complex. Nat Rev Mol Cell Biol. 2006, 7: 678-689. 10.1038/nrm2009.CrossRefPubMed
7.
go back to reference O’Neil J, Calvo J, McKenna K, Krishnamoorthy V, Aster JC, Bassing CH, Alt FW, Kelliher M, Look AT: Activating Notch1 mutations in mouse models of T-ALL. Blood. 2006, 107: 781-785. 10.1182/blood-2005-06-2553.PubMedCentralCrossRefPubMed O’Neil J, Calvo J, McKenna K, Krishnamoorthy V, Aster JC, Bassing CH, Alt FW, Kelliher M, Look AT: Activating Notch1 mutations in mouse models of T-ALL. Blood. 2006, 107: 781-785. 10.1182/blood-2005-06-2553.PubMedCentralCrossRefPubMed
8.
go back to reference Chan SM, Weng AP, Tibshirani R, Aster JC, Utz PJ: Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia. Blood. 2007, 110: 278-286. 10.1182/blood-2006-08-039883.PubMedCentralCrossRefPubMed Chan SM, Weng AP, Tibshirani R, Aster JC, Utz PJ: Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia. Blood. 2007, 110: 278-286. 10.1182/blood-2006-08-039883.PubMedCentralCrossRefPubMed
9.
go back to reference Real PJ, Tosello V, Palomero T, Castillo M, Hernando E, de Stanchina E, Sulis ML, Barnes K, Sawai C, Homminga I: Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med. 2009, 15: 50-58. 10.1038/nm.1900.PubMedCentralCrossRefPubMed Real PJ, Tosello V, Palomero T, Castillo M, Hernando E, de Stanchina E, Sulis ML, Barnes K, Sawai C, Homminga I: Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med. 2009, 15: 50-58. 10.1038/nm.1900.PubMedCentralCrossRefPubMed
10.
go back to reference Scortegagna M, Morris MA, Oktay Y, Bennett M, Garcia JA: The HIF family member EPAS1/HIF-2alpha is required for normal hematopoiesis in mice. Blood. 2003, 102: 1634-1640. 10.1182/blood-2003-02-0448.CrossRefPubMed Scortegagna M, Morris MA, Oktay Y, Bennett M, Garcia JA: The HIF family member EPAS1/HIF-2alpha is required for normal hematopoiesis in mice. Blood. 2003, 102: 1634-1640. 10.1182/blood-2003-02-0448.CrossRefPubMed
11.
go back to reference Hochachka PW, Buck LT, Doll CJ, Land SC: Unifying theory of hypoxia tolerance: molecular/metabolic defense and rescue mechanisms for surviving oxygen lack. Proc Natl Acad Sci U S A. 1996, 93: 9493-9498. 10.1073/pnas.93.18.9493.PubMedCentralCrossRefPubMed Hochachka PW, Buck LT, Doll CJ, Land SC: Unifying theory of hypoxia tolerance: molecular/metabolic defense and rescue mechanisms for surviving oxygen lack. Proc Natl Acad Sci U S A. 1996, 93: 9493-9498. 10.1073/pnas.93.18.9493.PubMedCentralCrossRefPubMed
12.
go back to reference Pugh CW, Ratcliffe PJ: Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med. 2003, 9: 677-684. 10.1038/nm0603-677.CrossRefPubMed Pugh CW, Ratcliffe PJ: Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med. 2003, 9: 677-684. 10.1038/nm0603-677.CrossRefPubMed
13.
go back to reference Semenza GL: Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol. 1999, 15: 551-578. 10.1146/annurev.cellbio.15.1.551.CrossRefPubMed Semenza GL: Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol. 1999, 15: 551-578. 10.1146/annurev.cellbio.15.1.551.CrossRefPubMed
14.
15.
go back to reference Matsunaga T, Imataki O, Torii E, Kameda T, Shide K, Shimoda H, Kamiunten A, Sekine M, Taniguchi Y, Yamamoto S: Elevated HIF-1alpha expression of acute myelogenous leukemia stem cells in the endosteal hypoxic zone may be a cause of minimal residual disease in bone marrow after chemotherapy. Leuk Res. 2012, 36: e122-124. 10.1016/j.leukres.2012.02.028.CrossRefPubMed Matsunaga T, Imataki O, Torii E, Kameda T, Shide K, Shimoda H, Kamiunten A, Sekine M, Taniguchi Y, Yamamoto S: Elevated HIF-1alpha expression of acute myelogenous leukemia stem cells in the endosteal hypoxic zone may be a cause of minimal residual disease in bone marrow after chemotherapy. Leuk Res. 2012, 36: e122-124. 10.1016/j.leukres.2012.02.028.CrossRefPubMed
16.
go back to reference Tanturli M, Giuntoli S, Barbetti V, Rovida E, Dello Sbarba P: Hypoxia selects bortezomib-resistant stem cells of chronic myeloid leukemia. PLoS One. 2011, 6: e17008-10.1371/journal.pone.0017008.PubMedCentralCrossRefPubMed Tanturli M, Giuntoli S, Barbetti V, Rovida E, Dello Sbarba P: Hypoxia selects bortezomib-resistant stem cells of chronic myeloid leukemia. PLoS One. 2011, 6: e17008-10.1371/journal.pone.0017008.PubMedCentralCrossRefPubMed
17.
go back to reference Raetz EA, Bhatla T: Where do we stand in the treatment of relapsed acute lymphoblastic leukemia?. Hematology Am Soc Hematol Educ Program. 2012, 2012: 129-136.PubMed Raetz EA, Bhatla T: Where do we stand in the treatment of relapsed acute lymphoblastic leukemia?. Hematology Am Soc Hematol Educ Program. 2012, 2012: 129-136.PubMed
18.
go back to reference Weber A, Taube S, Zur Stadt U, Horstmann M, Krohn K, Bradtke J, Teigler-Schlegel A, Leiblein S, Christiansen H: Quantification of minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL) using amplicon-fusion-site polymerase chain reaction (AFS-PCR). Exp Hematol Oncol. 2012, 1: 33-10.1186/2162-3619-1-33.PubMedCentralCrossRefPubMed Weber A, Taube S, Zur Stadt U, Horstmann M, Krohn K, Bradtke J, Teigler-Schlegel A, Leiblein S, Christiansen H: Quantification of minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL) using amplicon-fusion-site polymerase chain reaction (AFS-PCR). Exp Hematol Oncol. 2012, 1: 33-10.1186/2162-3619-1-33.PubMedCentralCrossRefPubMed
19.
go back to reference Trioche P, Nelken B, Michel G, Pellier I, Petit A, Bertrand Y, Rohrlich P, Schmitt C, Sirvent N, Boutard P: French “real life” experience of clofarabine in children with refractory or relapsed acute lymphoblastic leukaemia. Exp Hematol Oncol. 2012, 1: 39-10.1186/2162-3619-1-39.PubMedCentralCrossRefPubMed Trioche P, Nelken B, Michel G, Pellier I, Petit A, Bertrand Y, Rohrlich P, Schmitt C, Sirvent N, Boutard P: French “real life” experience of clofarabine in children with refractory or relapsed acute lymphoblastic leukaemia. Exp Hematol Oncol. 2012, 1: 39-10.1186/2162-3619-1-39.PubMedCentralCrossRefPubMed
20.
go back to reference Chen J, Imanaka N, Griffin JD: Hypoxia potentiates Notch signaling in breast cancer leading to decreased E-cadherin expression and increased cell migration and invasion. Br J Cancer. 2010, 102: 351-360. 10.1038/sj.bjc.6605486.PubMedCentralCrossRefPubMed Chen J, Imanaka N, Griffin JD: Hypoxia potentiates Notch signaling in breast cancer leading to decreased E-cadherin expression and increased cell migration and invasion. Br J Cancer. 2010, 102: 351-360. 10.1038/sj.bjc.6605486.PubMedCentralCrossRefPubMed
21.
go back to reference Zhong H, Mabjeesh N, Willard M, Simons J: Nuclear expression of hypoxia-inducible factor 1alpha protein is heterogeneous in human malignant cells under normoxic conditions. Cancer Lett. 2002, 181: 233-238. 10.1016/S0304-3835(02)00053-8.CrossRefPubMed Zhong H, Mabjeesh N, Willard M, Simons J: Nuclear expression of hypoxia-inducible factor 1alpha protein is heterogeneous in human malignant cells under normoxic conditions. Cancer Lett. 2002, 181: 233-238. 10.1016/S0304-3835(02)00053-8.CrossRefPubMed
22.
go back to reference Gustafsson MV, Zheng X, Pereira T, Gradin K, Jin S, Lundkvist J, Ruas JL, Poellinger L, Lendahl U, Bondesson M: Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev Cell. 2005, 9: 617-628. 10.1016/j.devcel.2005.09.010.CrossRefPubMed Gustafsson MV, Zheng X, Pereira T, Gradin K, Jin S, Lundkvist J, Ruas JL, Poellinger L, Lendahl U, Bondesson M: Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev Cell. 2005, 9: 617-628. 10.1016/j.devcel.2005.09.010.CrossRefPubMed
23.
go back to reference Pear WS, Simon MC: Lasting longer without oxygen: The influence of hypoxia on Notch signaling. Cancer Cell. 2005, 8: 435-437. 10.1016/j.ccr.2005.11.016.CrossRefPubMed Pear WS, Simon MC: Lasting longer without oxygen: The influence of hypoxia on Notch signaling. Cancer Cell. 2005, 8: 435-437. 10.1016/j.ccr.2005.11.016.CrossRefPubMed
24.
go back to reference Birner P, Schindl M, Obermair A, Breitenecker G, Oberhuber G: Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res. 2001, 7: 1661-1668.PubMed Birner P, Schindl M, Obermair A, Breitenecker G, Oberhuber G: Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res. 2001, 7: 1661-1668.PubMed
25.
go back to reference Koukourakis MI, Giatromanolaki A, Skarlatos J, Corti L, Blandamura S, Piazza M, Gatter KC, Harris AL: Hypoxia inducible factor (HIF-1a and HIF-2a) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy. Cancer Res. 2001, 61: 1830-1832.PubMed Koukourakis MI, Giatromanolaki A, Skarlatos J, Corti L, Blandamura S, Piazza M, Gatter KC, Harris AL: Hypoxia inducible factor (HIF-1a and HIF-2a) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy. Cancer Res. 2001, 61: 1830-1832.PubMed
26.
go back to reference Zhang H, Li H, Xi HS, Li S: HIF1alpha is required for survival maintenance of chronic myeloid leukemia stem cells. Blood. 2012, 119: 2595-2607. 10.1182/blood-2011-10-387381.PubMedCentralCrossRefPubMed Zhang H, Li H, Xi HS, Li S: HIF1alpha is required for survival maintenance of chronic myeloid leukemia stem cells. Blood. 2012, 119: 2595-2607. 10.1182/blood-2011-10-387381.PubMedCentralCrossRefPubMed
27.
go back to reference DeClerck YA, Mercurio AM, Stack MS, Chapman HA, Zutter MM, Muschel RJ, Raz A, Matrisian LM, Sloane BF, Noel A: Proteases, extracellular matrix, and cancer: a workshop of the path B study section. Am J Pathol. 2004, 164: 1131-1139. 10.1016/S0002-9440(10)63200-2.PubMedCentralCrossRefPubMed DeClerck YA, Mercurio AM, Stack MS, Chapman HA, Zutter MM, Muschel RJ, Raz A, Matrisian LM, Sloane BF, Noel A: Proteases, extracellular matrix, and cancer: a workshop of the path B study section. Am J Pathol. 2004, 164: 1131-1139. 10.1016/S0002-9440(10)63200-2.PubMedCentralCrossRefPubMed
28.
go back to reference Munoz-Najar UM, Neurath KM, Vumbaca F, Claffey KP: Hypoxia stimulates breast carcinoma cell invasion through MT1-MMP and MMP-2 activation. Oncogene. 2006, 25: 2379-2392. 10.1038/sj.onc.1209273.CrossRefPubMed Munoz-Najar UM, Neurath KM, Vumbaca F, Claffey KP: Hypoxia stimulates breast carcinoma cell invasion through MT1-MMP and MMP-2 activation. Oncogene. 2006, 25: 2379-2392. 10.1038/sj.onc.1209273.CrossRefPubMed
29.
go back to reference Ries C, Loher F, Zang C, Ismair MG, Petrides PE: Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes. Clin Cancer Res. 1999, 5: 1115-1124.PubMed Ries C, Loher F, Zang C, Ismair MG, Petrides PE: Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes. Clin Cancer Res. 1999, 5: 1115-1124.PubMed
30.
go back to reference Lin LI, Lin DT, Chang CJ, Lee CY, Tang JL, Tien HF: Marrow matrix metalloproteinases (MMPs) and tissue inhibitors of MMP in acute leukaemia: potential role of MMP-9 as a surrogate marker to monitor leukaemic status in patients with acute myelogenous leukaemia. Br J Haematol. 2002, 117: 835-841. 10.1046/j.1365-2141.2002.03510.x.CrossRefPubMed Lin LI, Lin DT, Chang CJ, Lee CY, Tang JL, Tien HF: Marrow matrix metalloproteinases (MMPs) and tissue inhibitors of MMP in acute leukaemia: potential role of MMP-9 as a surrogate marker to monitor leukaemic status in patients with acute myelogenous leukaemia. Br J Haematol. 2002, 117: 835-841. 10.1046/j.1365-2141.2002.03510.x.CrossRefPubMed
31.
go back to reference Zhang B, Wu KF, Cao ZY, Rao Q, Ma XT, Zheng GG, Li G: IL-18 increases invasiveness of HL-60 myeloid leukemia cells: up-regulation of matrix metalloproteinases-9 (MMP-9) expression. Leuk Res. 2004, 28: 91-95. 10.1016/S0145-2126(03)00121-8.CrossRefPubMed Zhang B, Wu KF, Cao ZY, Rao Q, Ma XT, Zheng GG, Li G: IL-18 increases invasiveness of HL-60 myeloid leukemia cells: up-regulation of matrix metalloproteinases-9 (MMP-9) expression. Leuk Res. 2004, 28: 91-95. 10.1016/S0145-2126(03)00121-8.CrossRefPubMed
32.
go back to reference Nardinocchi L, Puca R, Sacchi A, D’Orazi G: Inhibition of HIF-1alpha activity by homeodomain-interacting protein kinase-2 correlates with sensitization of chemoresistant cells to undergo apoptosis. Mol Cancer. 2009, 8: 1-PubMedCentralCrossRefPubMed Nardinocchi L, Puca R, Sacchi A, D’Orazi G: Inhibition of HIF-1alpha activity by homeodomain-interacting protein kinase-2 correlates with sensitization of chemoresistant cells to undergo apoptosis. Mol Cancer. 2009, 8: 1-PubMedCentralCrossRefPubMed
33.
go back to reference Sullivan R, Pare GC, Frederiksen LJ, Semenza GL, Graham CH: Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity. Mol Cancer Ther. 2008, 7: 1961-1973. 10.1158/1535-7163.MCT-08-0198.CrossRefPubMed Sullivan R, Pare GC, Frederiksen LJ, Semenza GL, Graham CH: Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity. Mol Cancer Ther. 2008, 7: 1961-1973. 10.1158/1535-7163.MCT-08-0198.CrossRefPubMed
34.
go back to reference Wang Z, Li Y, Kong D, Banerjee S, Ahmad A, Azmi AS, Ali S, Abbruzzese JL, Gallick GE, Sarkar FH: Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res. 2009, 69: 2400-2407. 10.1158/0008-5472.CAN-08-4312.PubMedCentralCrossRefPubMed Wang Z, Li Y, Kong D, Banerjee S, Ahmad A, Azmi AS, Ali S, Abbruzzese JL, Gallick GE, Sarkar FH: Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res. 2009, 69: 2400-2407. 10.1158/0008-5472.CAN-08-4312.PubMedCentralCrossRefPubMed
35.
go back to reference Phillips TM, Kim K, Vlashi E, McBride WH, Pajonk F: Effects of recombinant erythropoietin on breast cancer-initiating cells. Neoplasia. 2007, 9: 1122-1129. 10.1593/neo.07694.PubMedCentralCrossRefPubMed Phillips TM, Kim K, Vlashi E, McBride WH, Pajonk F: Effects of recombinant erythropoietin on breast cancer-initiating cells. Neoplasia. 2007, 9: 1122-1129. 10.1593/neo.07694.PubMedCentralCrossRefPubMed
36.
go back to reference Nefedova Y, Cheng P, Alsina M, Dalton WS, Gabrilovich DI: Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. Blood. 2004, 103: 3503-3510. 10.1182/blood-2003-07-2340.CrossRefPubMed Nefedova Y, Cheng P, Alsina M, Dalton WS, Gabrilovich DI: Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. Blood. 2004, 103: 3503-3510. 10.1182/blood-2003-07-2340.CrossRefPubMed
37.
go back to reference Nefedova Y, Sullivan DM, Bolick SC, Dalton WS, Gabrilovich DI: Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy. Blood. 2008, 111: 2220-2229. 10.1182/blood-2007-07-102632.CrossRefPubMed Nefedova Y, Sullivan DM, Bolick SC, Dalton WS, Gabrilovich DI: Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy. Blood. 2008, 111: 2220-2229. 10.1182/blood-2007-07-102632.CrossRefPubMed
38.
go back to reference Rohwer N, Dame C, Haugstetter A, Wiedenmann B, Detjen K, Schmitt CA, Cramer T: Hypoxia-inducible factor 1alpha determines gastric cancer chemosensitivity via modulation of p53 and NF-kappaB. PLoS One. 2010, 5: e12038-10.1371/journal.pone.0012038.PubMedCentralCrossRefPubMed Rohwer N, Dame C, Haugstetter A, Wiedenmann B, Detjen K, Schmitt CA, Cramer T: Hypoxia-inducible factor 1alpha determines gastric cancer chemosensitivity via modulation of p53 and NF-kappaB. PLoS One. 2010, 5: e12038-10.1371/journal.pone.0012038.PubMedCentralCrossRefPubMed
39.
go back to reference Pistollato F, Rampazzo E, Persano L, Abbadi S, Frasson C, Denaro L, D’Avella D, Panchision DM, Della Puppa A, Scienza R, Basso G: Interaction of hypoxia-inducible factor-1alpha and Notch signaling regulates medulloblastoma precursor proliferation and fate. Stem Cells. 2010, 28: 1918-1929. 10.1002/stem.518.PubMedCentralCrossRefPubMed Pistollato F, Rampazzo E, Persano L, Abbadi S, Frasson C, Denaro L, D’Avella D, Panchision DM, Della Puppa A, Scienza R, Basso G: Interaction of hypoxia-inducible factor-1alpha and Notch signaling regulates medulloblastoma precursor proliferation and fate. Stem Cells. 2010, 28: 1918-1929. 10.1002/stem.518.PubMedCentralCrossRefPubMed
40.
go back to reference Yu EZ, Li YY, Liu XH, Kagan E, McCarron RM: Antiapoptotic action of hypoxia-inducible factor-1 alpha in human endothelial cells. Lab Invest. 2004, 84: 553-561. 10.1038/labinvest.3700071.CrossRefPubMed Yu EZ, Li YY, Liu XH, Kagan E, McCarron RM: Antiapoptotic action of hypoxia-inducible factor-1 alpha in human endothelial cells. Lab Invest. 2004, 84: 553-561. 10.1038/labinvest.3700071.CrossRefPubMed
41.
go back to reference Gillespie DL, Whang K, Ragel BT, Flynn JR, Kelly DA, Jensen RL: Silencing of hypoxia inducible factor-1alpha by RNA interference attenuates human glioma cell growth in vivo. Clin Cancer Res. 2007, 13: 2441-2448. 10.1158/1078-0432.CCR-06-2692.CrossRefPubMed Gillespie DL, Whang K, Ragel BT, Flynn JR, Kelly DA, Jensen RL: Silencing of hypoxia inducible factor-1alpha by RNA interference attenuates human glioma cell growth in vivo. Clin Cancer Res. 2007, 13: 2441-2448. 10.1158/1078-0432.CCR-06-2692.CrossRefPubMed
42.
go back to reference Chen N, Chen X, Huang R, Zeng H, Gong J, Meng W, Lu Y, Zhao F, Wang L, Zhou Q: BCL-xL is a target gene regulated by hypoxia-inducible factor-1{alpha}. J Biol Chem. 2009, 284: 10004-10012. 10.1074/jbc.M805997200.PubMedCentralCrossRefPubMed Chen N, Chen X, Huang R, Zeng H, Gong J, Meng W, Lu Y, Zhao F, Wang L, Zhou Q: BCL-xL is a target gene regulated by hypoxia-inducible factor-1{alpha}. J Biol Chem. 2009, 284: 10004-10012. 10.1074/jbc.M805997200.PubMedCentralCrossRefPubMed
Metadata
Title
Notch1 is required for hypoxia-induced proliferation, invasion and chemoresistance of T-cell acute lymphoblastic leukemia cells
Authors
Jie Zou
Peng Li
Fei Lu
Na Liu
Jianjian Dai
Jingjing Ye
Xun Qu
Xiulian Sun
Daoxin Ma
Jino Park
Chunyan Ji
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2013
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/1756-8722-6-3

Other articles of this Issue 1/2013

Journal of Hematology & Oncology 1/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine